View on market: Stay Cautious, be with quality business:
US futures fell and Asian stocks were mixed Monday, amid challenges swirling around China and a reminder from Federal Reserve officials that their key objective is to fight high inflation. S&P 500 and Nasdaq 100 futures shed about 1%, while bourses in Japan, South Korea and Australia made modest headway. The caution follows the best month for global shares since 2020, which pared their slump this year to 16%. At 7:00 am, the Singapore-traded SGX Nifty — an early barometer of India’s benchmark Nifty 50 — traded 0.20% higher at 17,200 points. The dollar was steady, oil retreated and Bitcoin slid.
Economic Calendar:
- USD : ISM Manufacturing PMI (Jul) 01st Aug, 2022
- USD : JOLTs Job Openings (Jun) 02nd Aug, 2022
- USD : ISM Non-Manufacturing PMI (Jul) 03rd Aug, 2022
- INR : Trade Balance 02nd Aug, 2022
- INR : Interest Rate Decision 05th Aug, 2022
Q1FY23 Result Today: ITC, UPL, Max Financial, Varun Beverages, PDS, Escorts Kubota, Ramco Cement, Kansai Nerolac, Castrol India, Zomato, Indo Count, Alkyl Amines, Bajaj Consumer, Barbeque Nation
Q1FY23 Result:
Bank of Baroda Q1 FY23 (Consolidated, YoY) reported a 79.4% YoY growth in standalone profit at Rs 2,168 crore for the quarter ended June 2022, despite fall in other income and pre-provision operating profit. The significant decline in bad loans provisions aided the bottom line. Net interest income grew 12% YoY to Rs 8,838.4 crore in Q1FY23, with credit growth at 18 percent and 10.9% YoY increase in global deposits.
IDFC First Bank Q1 FY23 (Consolidated, YoY) recorded highest-ever standalone profit of Rs 474.33 crore in Q1FY23, against a loss of Rs 630 crore in the corresponding period of the previous fiscal. The increase in core operating income and fall in provisions aided the profitability, with the sequential growth in profit at 38%. Net interest income grew 26% to Rs 2,751.1 crore YoY during the quarter, with 39 bps YoY improvement in net interest margin at 5.89% for the quarter. But there was 38 bps decline in net interest margin on a sequential basis
Cipla Q1 FY23 (Consolidated, YoY) recorded a 4% YoY decline in consolidated profit at Rs 686 crore for the quarter ended June 2022 as EBITDA fell by 15 percent YoY to Rs 1,143 crore and revenue fell by 2.3 percent to Rs 5,375 crore in the same period. India business declined 8.4% to Rs 2,483 crore and North America business grew by 15.5% to Rs 1,199 crore in Q1FY23.
Brokerage Radar:
NOMURA ON CIPLA: Buy, TP Rs 1195; 1Q: Ahead of est; Higher other operating income & lower R&D spend contributed to beat; Decline in domestic sales by 8% lower than est; Despite high-cost pressure, delivered steady gross margin & EBITDA at 21.3% in 1HFY23, 160bp higher than est.
MS ON DLF: OW, TP Rs 417; 1Q Beat – Executing Well on All Fronts; Well positioned to benefit from strong resi demand with a deep pipeline of new launches & ready inventory; Overall focus remains on FCF generation & de-leveraging
CLSA ON TORRENT PHARMA: Buy, TP Rs 1880; 1Q largely in-line: Ebitda margins improve 4ppt QoQ to 30.3%; Double-digit growth in India continues & a strong outlook for Brazil; Co awaiting US FDA inspections at its Dahej & Indrad plants
International Markets:
U.S & Europe:
Particulars | 29th July | Chg. | Chg.(%) |
Nasdaq | 12390.69 | 228.1 | 1.88 |
Dow | 32845.13 | 315.5 | 0.97 |
FTSE | 7423.43 | 78.18 | 1.06 |
CAC | 6448.5 | 109.29 | 1.72 |
DAX | 13484.05 | 201.94 | 1.52 |
Dow Fut.* | 32755.00 | -90.1 | -0.27 |
Asian markets:
Particulars | 01st August | Chg. | Chg.(%) |
SGX Nifty | 17247 | 15.5 | 0.09 |
Nikkei | 27933.3 | 131.63 | 0.47 |
Straits Times | 3211.56 | -9.09 | -0.28 |
Hang Seng | 19974.2 | -182.4 | -0.9 |
Shanghai | 3242.87 | -10.37 | -0.32 |
ADR Watch:
Particulars | 29th July | Chg. | Chg.(%) |
Dr. Reddy | 51.5 | -0.8 | -1.59 |
HDFC Bank | 62.8 | 0.72 | 1.16 |
ICICI Bank | 20.78 | 0.14 | 0.68 |
Infosys | 19.49 | 0.34 | 1.78 |
Tata Motor | 28.52 | 0.33 | 1.17 |
Wipro | 5.30 | 0.06 | 1.15 |
Commodities & Currency:
Particulars | Current Price | Chg.(%) |
USD/INR | 79.25 | -0.63 |
Brent | 103.19 | -0.75 |
Gold | 1780.50 | -0.07 |
Silver | 20.188 | -0.04 |
FIIs & DII:
Particulars | 29th July | 28th July |
FIIs | 1046.32 | 1637.69 |
DIIs | -0.91 | 600.29 |
News Update:
Dr Reddy’s Laboratories: entered into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify in the US.
Zee Entertainment Enterprises: received no-objection letters from BSE and National Stock Exchange of India, for the proposed Composite Scheme of Arrangement amongst Zee Entertainment, Bangla Entertainment, and Culver Max Entertainment (formerly Sony Pictures Networks India).
Yes Bank: is going to raise Rs 8,898.47 crore from The Carlyle Group and Verventa Holdings (affiliate of Advent) by selling 10 percent stake each.
Source: Moneyontrol, Livemint,, Bloomberg, Investing
Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014
Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited, suhail@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL